References
- Armstrong SC, Cozza KL, Sandson NB. Six patterns of drug-drug interactions. Psychosomatics 2003;44:255-8
- Duda S, Aliferis C, Miller R, et al. Extracting drug-drug interaction articles from MEDLINE to improve the content of drug databases. AMIA Annu Symp Proc 2005;216-20
- Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8
- U.S. Food and Drug Administration. FDA Guidance: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm091593.pdf [Last accessed 14/04/2010]
- U.S. Food and Drug Administration. FDA Guidance: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. Draft Guidance. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm091593.pdf [Last accessed 25/03/2010]
- Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm Suppl 2003;64:105-17
- McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64:984-9
- Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004;45:460-8
- Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005;66:27-33
- Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66:183-94; quiz 147, 273-184
- de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-73
- Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007;40:77-97
- Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28:99-112
- Sharif ZA. Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Prim Care Companion J Clin Psychiatry 2003;5:22-5
- de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. Am J Psychiatry 2004;161:1-56
- Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10,11-epoxide by quetiapine. Pharmacotherapy2002;22:1500-3
- Duggal HS, Fetchko J. Serotonin syndrome and atypical antipsychotics. Am J Psychiatry 2002;159:672-3
- Kohen I, Gordon ML, Manu P. Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports. CNS Spectr 2007;12:596-8
- Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, et al. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:407-9
- Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006;68:684-91
- Aparasu RR, Jano E, Bhatara V. Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm 2009;5:234-41
- Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6
- Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84
- Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28:17-29
- Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26
- Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88
- Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002;28:589-605
- Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-9
- Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-9
- Zhu B, Ascher-Svanum H, Faries DE, et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008;8:19
- Saverno KR, Malone DC, Kurowsky J. Pharmacy students' ability to identify potential drug-drug interactions. Am J Pharm Educ 2009;73:27
- Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism, and excretion of a single oral dose of 14C-paliperidone 1 mg in five healthy male subjects (abstract). Clin Pharmacol Ther 2006;79:80
- Groves RM. Theories and methods of telephone surveys. Annu Rev Sociol. 1990;16:221-40
- Lesser VM, Kalsbeek WD. Nonsampling errors in environmental surveys. J Agric Biol Environ Stat 1999;4:473-88
- Adams AS, Soumerai SB, Lomas J, et al. Evidence of self-report bias in assessing adherence to guidelines. Int J Qual Health Care 1999;11:187-92
- Scully JH, Wilk JE. Selected characteristics and data of psychiatrists in the United States, 2001-2002. Acad Psychiatry 2003;27:247-51